Maximizing antigen targeting to the proteasome for gene-based vaccines

Helen A. Andersson, Michael A Barry

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Wild-type or immunoevasive antigens can drive weak CD8+ T-cell responses against both dominant and subdominant epitopes during gene-based vaccination. For many antigens, fusion to ubiquitin (Ub) to target them to the proteasome circumvents this problem. Although this procedure works in most cases, for one subset of antigens, Ub fusion does not improve immune responses. To determine why these failures occur, we have evaluated in detail the 'rules' for proteasome targeting that have been applied in mammalian vaccine studies, but that were actually defined in yeast systems. To do this, we fused a series of engineered Ub genes to green fluorescent protein (GFP) and tested their ability to target GFP to the proteasome for enhanced antigen processing and CD8+ T-cell responses. Here we demonstrate that Ub fusion mediates enhanced CD8+ responses by proteasome targeting rather than by enhancing protein translation. We also show that several of the yeast-defined Ub constructs failed to target the proteasome in mammalian cells and likewise failed to enhance transgene-specific CD8+ T-cell responses in mice. In contrast, when mammalian-optimized constructs were applied to target the influenza virus nucleoprotein, CD8+ responses were enhanced against its refractory subdominant epitope in mice. This work demonstrates that Ub fusion has efficacy to enhance CD8+ responses, especially against subdominant antigen epitopes, provided constructs are optimized for mammalian use.

Original languageEnglish (US)
Pages (from-to)432-446
Number of pages15
JournalMolecular Therapy
Volume10
Issue number3
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Vaccines
Antigens
Genes
Epitopes
Green Fluorescent Proteins
T-Lymphocytes
Yeasts
Nucleoproteins
Antigen Presentation
Protein Biosynthesis
Orthomyxoviridae
Transgenes
Vaccination

Keywords

  • Genetic immunization
  • Proteasome targeting
  • Ubiquitin

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Maximizing antigen targeting to the proteasome for gene-based vaccines. / Andersson, Helen A.; Barry, Michael A.

In: Molecular Therapy, Vol. 10, No. 3, 09.2004, p. 432-446.

Research output: Contribution to journalArticle

@article{c8af8f0a2716426a927b73828873a752,
title = "Maximizing antigen targeting to the proteasome for gene-based vaccines",
abstract = "Wild-type or immunoevasive antigens can drive weak CD8+ T-cell responses against both dominant and subdominant epitopes during gene-based vaccination. For many antigens, fusion to ubiquitin (Ub) to target them to the proteasome circumvents this problem. Although this procedure works in most cases, for one subset of antigens, Ub fusion does not improve immune responses. To determine why these failures occur, we have evaluated in detail the 'rules' for proteasome targeting that have been applied in mammalian vaccine studies, but that were actually defined in yeast systems. To do this, we fused a series of engineered Ub genes to green fluorescent protein (GFP) and tested their ability to target GFP to the proteasome for enhanced antigen processing and CD8+ T-cell responses. Here we demonstrate that Ub fusion mediates enhanced CD8+ responses by proteasome targeting rather than by enhancing protein translation. We also show that several of the yeast-defined Ub constructs failed to target the proteasome in mammalian cells and likewise failed to enhance transgene-specific CD8+ T-cell responses in mice. In contrast, when mammalian-optimized constructs were applied to target the influenza virus nucleoprotein, CD8+ responses were enhanced against its refractory subdominant epitope in mice. This work demonstrates that Ub fusion has efficacy to enhance CD8+ responses, especially against subdominant antigen epitopes, provided constructs are optimized for mammalian use.",
keywords = "Genetic immunization, Proteasome targeting, Ubiquitin",
author = "Andersson, {Helen A.} and Barry, {Michael A}",
year = "2004",
month = "9",
doi = "10.1016/j.ymthe.2004.05.035",
language = "English (US)",
volume = "10",
pages = "432--446",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Maximizing antigen targeting to the proteasome for gene-based vaccines

AU - Andersson, Helen A.

AU - Barry, Michael A

PY - 2004/9

Y1 - 2004/9

N2 - Wild-type or immunoevasive antigens can drive weak CD8+ T-cell responses against both dominant and subdominant epitopes during gene-based vaccination. For many antigens, fusion to ubiquitin (Ub) to target them to the proteasome circumvents this problem. Although this procedure works in most cases, for one subset of antigens, Ub fusion does not improve immune responses. To determine why these failures occur, we have evaluated in detail the 'rules' for proteasome targeting that have been applied in mammalian vaccine studies, but that were actually defined in yeast systems. To do this, we fused a series of engineered Ub genes to green fluorescent protein (GFP) and tested their ability to target GFP to the proteasome for enhanced antigen processing and CD8+ T-cell responses. Here we demonstrate that Ub fusion mediates enhanced CD8+ responses by proteasome targeting rather than by enhancing protein translation. We also show that several of the yeast-defined Ub constructs failed to target the proteasome in mammalian cells and likewise failed to enhance transgene-specific CD8+ T-cell responses in mice. In contrast, when mammalian-optimized constructs were applied to target the influenza virus nucleoprotein, CD8+ responses were enhanced against its refractory subdominant epitope in mice. This work demonstrates that Ub fusion has efficacy to enhance CD8+ responses, especially against subdominant antigen epitopes, provided constructs are optimized for mammalian use.

AB - Wild-type or immunoevasive antigens can drive weak CD8+ T-cell responses against both dominant and subdominant epitopes during gene-based vaccination. For many antigens, fusion to ubiquitin (Ub) to target them to the proteasome circumvents this problem. Although this procedure works in most cases, for one subset of antigens, Ub fusion does not improve immune responses. To determine why these failures occur, we have evaluated in detail the 'rules' for proteasome targeting that have been applied in mammalian vaccine studies, but that were actually defined in yeast systems. To do this, we fused a series of engineered Ub genes to green fluorescent protein (GFP) and tested their ability to target GFP to the proteasome for enhanced antigen processing and CD8+ T-cell responses. Here we demonstrate that Ub fusion mediates enhanced CD8+ responses by proteasome targeting rather than by enhancing protein translation. We also show that several of the yeast-defined Ub constructs failed to target the proteasome in mammalian cells and likewise failed to enhance transgene-specific CD8+ T-cell responses in mice. In contrast, when mammalian-optimized constructs were applied to target the influenza virus nucleoprotein, CD8+ responses were enhanced against its refractory subdominant epitope in mice. This work demonstrates that Ub fusion has efficacy to enhance CD8+ responses, especially against subdominant antigen epitopes, provided constructs are optimized for mammalian use.

KW - Genetic immunization

KW - Proteasome targeting

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=4444349861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444349861&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.05.035

DO - 10.1016/j.ymthe.2004.05.035

M3 - Article

C2 - 15336644

AN - SCOPUS:4444349861

VL - 10

SP - 432

EP - 446

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -